Changes in cholesterol and triglyceride concentrations in the Vanguard population of the Carotene and Retinol Efficacy Trial (CARET).
BACKGROUND
The Beta-Carotene and Retinol Efficacy Trial (CARET) was terminated 21 months ahead of schedule due to an excess of lung cancers. Deaths from cardiovascular disease also increased (relative risk=1.26 (95% confidence interval (CI) 0.99-1.61)) in the group assigned to a combination of 30 mg beta-carotene and 25 000 IU retinyl palmitate (vitamin A) daily. The basis for increased cardiovascular mortality is unexplained.


METHODS
We analyzed data on serum lipids, available for 1474 CARET Vanguard participants who were enrolled in the two CARET pilot studies and transitioned to the Vanguard study. Total cholesterol and triglycerides were measured 2 months prior to, 4 and 12 months following randomization, and annually thereafter for up to 7 y.


METHODS
In the asbestos-exposed pilot (N = 816), participants were assigned to beta-carotene and retinol or to placebo; in the smokers pilot (N = 1029), participants were assigned to beta-carotene, retinol, a combination, or placebo.


RESULTS
Serum cholesterol showed a decline over time in both arms; serum triglycerides had a continuous decline over time in the placebo arm, but an initial increase that persisted in the active arm. Both serum cholesterol concentrations (P < 0.0003) and serum triglycerides (P < 0.0001) were significantly higher in the participants receiving vitamin A and/or a combination of vitamin A and beta-carotene (n = 863) as compared to the placebo group (n = 611). Those in this active intervention group had an average cholesterol concentration 5.3 mg/dl (0.137 mmol/l) higher than those in the placebo arm.


CONCLUSIONS
The differences in cholesterol and triglyceride concentrations between the groups following randomization may account in part for the unexpected excess in cardiovascular deaths seen in the active intervention arm of CARET.
Cartmel
B
B
Department of Epidemiology and Public Health and the Yale Cancer Center, Yale University School of Medicine, New Haven, CT 06510, USA. brenda.cartmel@yale.edu
Dziura
J
J
Cullen
M R
MR
Vegso
S
S
Omenn
G S
GS
Goodman
G E
GE
Redlich
C A
CA
D000975:Antioxidants / Q000008:administration & dosage / Q000009:adverse effects*; D001194:Asbestos / Q000009:adverse effects; D002318:Cardiovascular Diseases / Q000097:blood / Q000139:chemically induced / Q000401:mortality*; D002338:Carotenoids / Q000008:administration & dosage / Q000009:adverse effects*; D002784:Cholesterol / Q000097:blood*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D012307:Risk Factors; D012907:Smoking / Q000009:adverse effects; D014280:Triglycerides / Q000097:blood*; D014801:Vitamin A / Q000008:administration & dosage / Q000009:adverse effects*
D000975:Antioxidants; D014280:Triglycerides; D014801:Vitamin A; D001194:Asbestos; D002338:Carotenoids; D002784:Cholesterol